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Summary
Objective: Osteoarthritis is a disease process of cellular degradation of articular cartilage caused by mechanical loads and inﬂammatory
cytokines. We studied the cellular response in native cartilage subjected to a mechanical load administered simultaneously with an inﬂamma-
tory cytokine interleukin-1 (IL-1), hypothesizing that the combination of load and cytokine would result in accelerated extracellular matrix
(ECM) degradation.
Methods: Mature bovine articular cartilage was loaded for 3 days (stimulation) with 0.2 and 0.5 MPa stresses, with and without IL-1 (IL-1a,
10 ng/ml), followed by 3 days of no stimulation (recovery). Aggrecan and collagen loss were measured as well as aggrecan cleavage using
monoclonal antibodies AF-28 and BC-3 for cleavage by aggrecanases (ADAMTS) and matrix metalloproteinases (MMPs), respectively.
Results: Incubation with IL-1 caused aggrecan cleavage by aggrecanases and MMPs during the 3 days of stimulation. A load of 0.5 MPa
inhibited the IL-1-induced aggrecan loss while no inhibition was found for the 0.2 MPa stress. There was no collagen loss during the treat-
ments but upon load and IL-1 removal proteoglycan and collagen loss increased. Load itself under these conditions was found to have no
effect when compared to the unloaded controls.
Conclusions: A mechanical load of sufﬁcient magnitude can inhibit ECM degradation by chondrocytes when stimulated by IL-1. The molecular
mechanisms involved in this process are not clear but probably involve altered mechanochemical signal transduction between the ECM and
chondrocyte.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a pathological condition of articular
cartilage associated with extracellular matrix (ECM) degra-
dation related to mechanical (wear-and-tear, high stress,
trauma) and inﬂammatory (physicochemical) mechanisms,
both of which have been shown to increase enzyme synthe-
sis by chondfrocytes1e4. Matrix metalloproteinases1, 3 &
13 (MMPs) and aggrecanases1 & 2 (i.e., e A Disintegrin
And Metalloproteinase with ThromboSpondin-like motifs
(ADAMTS) 4 & 5) are important enzymes responsible for
the degradation of articular cartilage. Both enzymes cleave
aggrecan within the interglobular domain (IGD) between the
G1 and G2 regions, MMPs at the Asn341-Phe342 site and
ADAMTS-4 & 5 at the Glu373-Ala374 site2,3,5e7. Each cleav-
age site produces a unique neoepitope which can be recog-
nized by speciﬁc antibodies. Several studies have
hypothesized that aggrecanase is the primary enzyme
responsible for aggrecan proteolysis in the early stages
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97collagen cleavage by MMPs2,3,7. These studies used
physiochemically induced models of OA in which Interleu-
kin-1 (IL-1) was used to stimulate a catabolic response by
the chondrocytes. While the inﬂammatory-induced injury
model of OA has been well characterized, the mechanically
induced injury model of OA is not.
Several mechanically induced in-vitro cell and tissue in-
jury models have reported increased synthesis of MMPs
and ECM degradation while one study found increased ag-
grecanase but only at the messenger level4,8e15. Recent
evidence indicates that the mechanical and inﬂammatory
mechanisms may be synergistic, resulting in a mechanically
induced down-regulation of the cellular catabolic response
caused by IL-1 stimulation16e21. Thus, a mechanical load
appears to inhibit the cleavage of aggrecan induced by
IL-1 stimulation. Based on previous investigations4,12,22,
we hypothesized that different magnitudes of load applied
in the presence of an inﬂammatory cytokine (IL-1) might
result in different mechanisms of cellular catabolism of the
ECM. To test this hypothesis we measured aggrecan loss
and cleavage before, during and after subjecting mature
bovine cartilage to inﬂammatory (10 ng/ml of IL-1a) and
mechanical (0.2 and 0.5 MPa) stimulations. We found that
when stimulated with IL-1 both aggrecanases and MMPs
degraded the ECM (aggrecan and collagen) in unloaded
and 0.2 MPa loaded cartilage while the 0.5 MPa load was
found to completely inhibited the cellular catabolism of the
98 P. A. Torzilli et al.: Load inhibits IL-1 cartilage degradationECM produced by the IL-1 stimulation. Although several
studies have reported preventative affects of load on
IL-1-induced matrix degradation in isolated chondrocyte
systems, to our knowledge this is the ﬁrst report document-
ing that mechanical loading of native articular cartilage can
inhibit chondrocyte catabolic degradation of the ECM when
stimulated by IL-1.Materials and methodsCHEMICALSUnless otherwise stated, all chemicals were purchased from Sigma (St.
Louis, MO) or Gibco BRL (Grand Island, NY). Culture media (CM) consisted
of Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) containing 1% antibiotic/
antimycotic (ABAM), 10 mM HEPES buffer and 50 mg/mL ascorbic acid,
used as is or supplemented with 10% fetal bovine serum (FBS) or 1%
ITSþ (insulin, human transferrin, and selenous acid, BD Biosciences, Frank-
lin Lakes, NJ) as described below. IL-1a and IL-1b was obtained from R&D
Systems (Minneapolis, MN), aggrecanase-1 and MMPs-1, 3 and 13 from
Chemicon International (Temecula, CA), and chondroitinase ABC, kerata-
nase and keratanase II from Seikagaku (Tokyo, Japan). Monoclonal anti-
bodies (Mab) AF-28 and BC-3 for aggrecan cleavage sites within the IGD
were obtained from Chemicon and Abcam (Cambridge, MA), respectively,
and Mab G1, which recognizes the G1 domain within aggrecan, was kindly
provided by Dr Peter J. Roughley (Shriners Hospital, McGill University, Mon-
treal, Canada).TISSUE PREPARATIONMature bovine knees (young adult 18e24 months old) were obtained from
a local abattoir within 24 h postmortem. Seven-millimeter diameter full-thick-
ness (w1.5 mm) cartilage discs (explants) were removed from the underly-
ing bone in the load-bearing regions of the trochlear notch using a biopsy
punch and surgical blade. The explants were separated into 24-well plates
containing CMþ 10% FBS and incubated at 100% humidity, 5% C02 and
95% air at 37C for 4 days (denoted as days 6 to 2, Fig. 1). The media
was replaced with CMþ 1% ITS, the explants incubated for another 2
days (days 2 to 0), and the media from the last day (day 0) used to com-
pare the initial 24-hour proteoglycan (PG) loss between the different treat-
ment groups as described below. For specimens analyzed for aggrecanFig. 1. Cartilage specimens were removed from mature bovine
knees (day 6) and incubated (Pretreatment) for 5 days (days
6 to 1) in culture media supplemented with 10% FBS (4 days)
or 1% ITS (1 day); all media was discarded. The specimens were
then separated into four treatment groups (Control, IL-1, Load,
Loadþ IL-1), incubated in culture media for one additional day
(days 1 to 0), and the media sampled (day 0), Treatments began
on day 0 (Treatment) and continued for 3 days, with media sampled
at 1, 3, 6, 9 and 24 h for the ﬁrst day and at 24 h intervals thereafter.
On day þ3 the treatments were removed (Recovery) and the media
sampled on each day. Analyses for PG and collagen content in the
media and explant were performed.cleavage using Mab the ITSþ was not included in the media to avoid non-
speciﬁc cross-reaction with the antibodies. Separate tests found no effect
of ITSþ on PG loss in any treatment group (data not shown).EFFECT OF IL-1a AND IL-1b ON PROTEOGLYCAN LOSSPreliminary studies were performed to measure the PG loss in cartilage
explants exposed to different concentrations of IL-1a and IL-1b over a 6-
day period. Explants (N¼ 5 each treatment) were incubated with IL-1a or
IL-1b at concentrations of 0, 0.1, 1, 10 or 100 ng/ml for 6 days. The media
was collected at the end of each day with total PG content in the media
(days 0e6) and explant (day 6) determined as described below.MECHANICAL LOADING PROTOCOLMechanical loading of the explant was performed using a Mechanical
Explant Test System (METS, Fig. 2), as previously described12,23,24. The
explants were cyclically loaded with a peak stress of 0.2 or 0.5 MPa (0-to-
peak, sinusoidal waveform, 0.5 Hz). Four treatment groups (N¼ 10 explants
each) were used: (1) unloaded explants (Control), (2) unloaded explants
stimulated with 10 ng/ml of IL-1a (IL-1), (3) loaded explants (Load), and (4)
loaded explants stimulated with 10 ng/ml of IL-1a (Loadþ IL-1). Stimulation
by mechanical load and IL-1a, individually and in combination, was applied
for 3 days (stimulation phase) followed by 6 or 3 days of no stimulation (re-
covery phase) for the 0.2 and 0.5 MPa tests, respectively. Media was ex-
changed every 24 h for the 0.2 MPa groups and for the 0.5 MPa groups at
1, 3, 6, 9 and 24 h, then every 24 h thereafter.ANALYSIS OF CELL DEATHCell viability was assessed at harvest and each time interval. Aw0.5 mm
specimen was removed perpendicular to the articular surface, incubated in
60 mM propidium iodide (indicator of cell death) and 10 mM ﬂuorescein diac-
etate (indicator of cell viability), washed, and imaged using a ﬂuorescent
microscope (excitation 488 nm; wavelength’s 535 and 630 nm, respectively;
Nikon Optiphot-2, Melville, NY) and CCD camera (Optronics, Goleta, CA).PROTEOGLYCAN AND COLLAGEN LOSSEach explant was digested at the end of the experiment with papain
(1 mg/ml at 65 C for 4 h) and the PG content (sulfated glycosaminoglycans
or GAGs) in the explant digest and media determined using the dimethyl-
methylene blue (DMMB) assay25. Likewise collagen content (0.5 MPa
only) was determined using the hydroxyproline assay26.ANALYSIS OF ENZYME-GENERATED AGGRECAN FRAGMENTSIn brief, proteoglycans were extracted from the explant and media using
4 M GuHCl in sodium acetate buffer solution, deglycosylated with keratanase
(0.001 U/mg GAG), keratanase II (0.001 U/mg GAG) and chondroitinase ABC
(0.001 U/mg GAG), and analyzed using Western blots. Western blot analysis
was performed using Mab BC-3 for detection of aggrecanase generated ag-
grecan cleavage at the N-terminal ARGS fragment at the Asn373-Ala374
bond27, and Mabs AF-28 and BC-14 were used for detection of MMP medi-
ated cleavage, both of which recognize the N-terminal FFGV fragment at the
Asn341-Phe342 bond28. As a positive control, puriﬁed bovine aggrecan
(10 mg/ml) was digested with human recombinant aggrecanase-1 and
MMPs-1, 3 and 13, all activated with 1 mM APMA. To ensure that the aggre-
can and its catabolites were deglycosylated, Western blot analysis was
performed using Mab G1.STATISTICAL ANALYSISFor each explant, PG and collagen released to the media were normal-
ized to their total (initial) contents at the start of the experiment (day 1) prior
to mechanical and IL-1 stimulation on day 0 (total¼ digestþmedia summed
over all times). PG content and PG and collagen losses were averaged for
each treatment and plotted as a function of post-treatment time, with the
day 1 and day 0 values used to compare baseline (starting) values for
each treatment group. Differences between treatment groups were analyzed
using the unpaired Student’s (two-tailed) t-test and analysis of variance
(ANOVA) (Systat, SPSS, Chicago, IL; Excel, Microsoft, Redmond, WA). Tur-
key/Kramer post-hoc analysis was used to determine statistical differences
for temporal responses within each treatment group. All data are expressed
as mean standard deviation unless otherwise indicated. The statistical sig-
niﬁcance level (a) was set at 0.05.
Fig. 2. The METS consists of dual 10-well loading chambers (bottom left) controlled by a personal computer interfaced with an electronic pneu-
matic controller (top left). The full-depth cartilage explant is conﬁned laterally with its articular surface in contact with the culture media (right). A
uniaxial compressive load is applied to the articular surface by a porous load platen attached to the piston of the air cylinder. Modiﬁed from
Lucchinetti et al.24
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DEPENDENTCartilage explants were incubated over a 6-day period
with IL-1a or IL-1b at concentrations of 0, 0.1, 1, 10 or
100 ng/ml and the PG content remaining in each explant
normalized by its initial PG content (day 1) (Fig. 3).
For the control groups (no IL-1) the mean PG loss per day
was 3.4% 2.2% (N¼ 80, r¼ 0.842). Both IL-1a and IL-
1b induced almost identical catabolic responses that were
dose and time dependent. At 10 ng/ml the PG loss per
day due to IL-1a and IL-1b was 10.6% 6.2% (r¼ 0.869)
and 11.3% 5.9% (r¼ 0.891), respectively, not signiﬁcantly
different (P> 0.5). Thus, for the remainder of the experi-
ments we used IL-1a at a concentration of 10 ng/ml.CELLS REMAIN VIABLE IN RESPONSE TO MECHANICAL
LOADING AND IL-1For each treatment group cell viability was assessed at
the end of each experiment using a live/dead cell assay.
There was no signiﬁcant cell death in any treatment group
at the time of harvest, on day 0 before the start of the me-
chanical and IL-1 stimulations, and at the end of each ex-
periment (data not shown). We were thus conﬁdent that
any PG loss from the explant was due solely to the mechan-
ical or IL-1 stimulations and not cell death.MECHANICAL LOAD AT 0.2 MPa DID NOT INHIBIT PG LOSS DUE
TO IL-1 STIMULATIONExplants were cyclically loaded for 3 days with a stress of
0.2 MPa 10 ng/ml of IL-1a and compared to control (no
load, no IL-1a) and IL-1a stimulated explants. The PG
loss on day 0, 24 h prior to mechanical and IL-1a stimula-
tions, was the same for all treatment groups indicating uni-
formity of PG loss before application of the mechanical and
IL-1a stimulations (Fig. 4). PG loss in the Control and Load
groups were similar on all days (days 0e9). PG loss in the
IL-1 group was elevated on all days and the addition of the
0.2 MPa stress did not effect the PG loss caused by expo-
sure to IL-1a. When the load and IL-1a were removed (day
3), the IL-1a stimulated groups (load) did not return to the
non-IL-1a stimulated PG loss values until day 6 or later.MECHANICAL LOAD AT 0.5 MPa INHIBITS PG LOSS DUE TO IL-1
STIMULATIONA mechanical load of 0.5 MPa was continuously applied
to explants for 3 days (10 ng/ml of IL-1a) and the PG
loss to the media measured after 1, 3, 6, 9, 24, 48 and
72 h. Thereafter the load and IL-1a stimulations were re-
moved for an additional 3 days (recovery) and the PG
loss measured every 24 h. Similar to the 0.2 MPa load,
the 0.5 MPa load did not affect the PG loss in non-IL-1a
stimulated explants during loading and recovery (Load vs
Control, Fig. 5).
For the ﬁrst 9 h of treatment with IL-1a, the PG loss in the
IL-1a and Loadþ IL-1a groups were not different from the
Control and Load groups. Over the next 15 h, however,
the PG loss in the IL-1a group signiﬁcantly increased
(P< 0.01; see 24 h, Fig. 5) while the addition of the me-
chanical load inhibited the PG loss (Loadþ IL-1a vs IL-1a,
0.1>P> 0.05), though not to the level of the controls
(Loadþ IL-1a vs Controls, P< 0.02). For longer incubation
times (24 h), IL-1a stimulation increased the PG loss from
1.6 fold at 24 h to 4.3 and 3.7 fold by days 2 and 3, respec-
tively (IL-1a vs Controls, Fig. 5). Application of the 0.5 MPa
mechanical load signiﬁcantly inhibited the IL-1a induced PG
loss on days 2 and 3 by 3.1 and 2.3 fold, respectively, how-
ever, not to the control levels (Loadþ IL-1a vs IL-1a, Fig. 5).
After removing the load and IL-1a stimulations the PG
loss for the IL-1a group decreased by almost 3 fold, return-
ing to the control levels on day 6. However, the PG loss in
the Loadþ IL-1a group continued to increase (1.9 fold) on
day 4 and then slowly decreased over the next 2 days but
never reached the control values (P< 0.001, Fig. 5).MECHANICAL LOADING AT 0.5 MPa INHIBITED COLLAGEN
LOSS DUE TO IL-1 STIMULATIONFor explants loaded with 0.5 MPa, collagen loss to the
media per day (micrograms) was measured in a subset of
explants (N¼ 3 with greatest PG loss) and normalized to
the initial collagen content (milligrams, day 1). The colla-
gen loss in the Control and Load groups did not change
compared to their baseline loss on day 0 (Fig. 6). In the
IL-1a group collagen loss did not change for days 1e3
but signiﬁcantly increased (w100e200 fold) on days 4e6
after IL-1a removal. In the Loadþ IL-1a group, the collagen
loss did not change during stimulation and 1 day after
Fig. 3. Cartilage explants were incubated for 24 h in IL-1 free media (days 1 to 0) and then were exposed on day 0 to (a) IL-1a and (b) IL-1b
at concentrations of 0, 0.1, 1, 10 and 100 ng/ml for 6 days (days 1e6). The PG content remaining in the explant on each day was determined
from the PG released to the media on each day and the PG remaining in the explant on day 6. Media and IL-1 were exchanged on each day.
All groups had similar PG contents at the time of IL-1 administration on day 0. The 0 and 10 ng/ml concentrations are highlighted. Data are
means S.E.M. for n¼ 5 explants.
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but not to the level of the IL-1a group (47% and 53%,
respectively).MECHANICAL LOADING INHIBITED AGGRECAN CLEAVAGE BY
MMPs AND AGGRECANASESThe aggrecan released into the media was analyzed us-
ing Western blots to determine the enzyme speciﬁc site of
aggrecan cleavage. Cleavage within the IGD between G1
and G2 was analyzed using BC-3 Mab to detect aggreca-
nase generated cleavage and AF-28 and BC-14 Mab to de-
tect MMP cleavage. In addition G1 Mab was used to
recognize the G1 domain at the N terminal of the aggrecan.Two explants were analyzed from each treatment group
having similar responses as shown in Figs. 5 and 6, and
having the greatest PG loss. The later criteria was chosen
to maximize the amount of aggrecan fragmentation for de-
tection of the speciﬁc cleavage sites. To further conﬁrm
the aggrecan cleavage results from this subset, additional
Western blot analyses were performed on a separate set
of explants similarly stimulated (0.5 MPa, IL-1a 10 ng/ml)
for 3 days plus 1 day of recovery (data not shown). A min-
imum of two positive specimens out of four analyses were
used to validate speciﬁcity of aggrecan cleavage sites.
A representative Western blot for all days is shown in
Fig. 7. There were no aggrecan fragments (cleavage prod-
ucts) found in the media of the Control group on any of the
Fig. 4. All treatment groups (Controls: solid line; IL-1a: solid line; Load: dashed line; Loadþ IL-1a:> dotted line) were incubated for
24 h without any treatment, exposed on day 0 (Stimulated) to IL-1a (10 ng/ml), Load (0.2 MPa) and Loadþ IL-1a for 3 days (days 0e3), and
the treatments removed on day 4 (Recovery) for another 6 days (days 4e9). The PG loss to the media per day was normalized to the initial PG
content in the explant. All groups had similar initial PG contents at the start of the experiment (day 1, data not shown), and similar PG loss
during the 24 h prior to treatment (day 0). Load did not affect the IL-1-induced PG catabolism. Data are means S.E.M. for n¼ 10 explants.
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released to the media on days 1e3, when the IL-1a was
present within the culture medium, and 1 day after IL-1a re-
moval from the media. Further aggrecan cleavage by either
enzyme was not detected (days 5 and 6). The fragments on
days 1e4 were generated by aggrecanase and MMP cleav-
age within the aggrecan’s IGD at the Asn373-Ala374 and
Asn341-Phe342 sites, respectively. The greatest amount of
fragments by both enzymes occurred on day 2.Fig. 5. All treatment groups (Controls: solid line; IL-1a: solid line; Loa
24 h without treatment, exposed on day 0 (0 h) to IL-1a (10 ng/ml), Load (
removed on day 4 (72 h) for another 3 days (72e144 h). PG loss to the
PG content (day 1). All groups had similar PG loss at the start of the e
the IL-1 induced PG catabolism by 24 h, and while still inhibiting the PG ca
load is removed on day 3. Data are mNo aggrecan fragments were found in the media of the
Load group on any day nor for the Loadþ IL-1a group on
days 0e3 (Fig. 7). However, aggrecan fragments were
found in the media of the Loadþ IL-1a group 3 day after
load and IL-1a removal (day 4). These fragments were gen-
erated by aggrecanase and MMP cleavage in about equal
amounts.
Aggrecan cleavage (nonspeciﬁc) was further conﬁrmed
using G1 Mab (Fig. 7). Aggrecan fragments were found ind: dashed line; Loadþ IL-1a:> dotted line) were incubated for
0.5 MPa) and Loadþ IL-1a for 3 days (0e72 h), and the treatments
media at each time interval (per hour) was normalized to the initial
xperiment (day 0). Load can now clearly be seen to start inhibiting
tabolism there is a continual increase in the rate of PG loss until the
eans S.E.M. for n¼ 10 explants.
Fig. 6. Collagen loss to the media on each day (Controls: solid line; IL-1a: solid line; Load: dashed line; Loadþ IL-1a:> dotted line)
was normalized to the initial collagen content (day 1). There was minimal collagen loss in all groups during the treatment interval (Stimulated,
days 0e3). After treatment removal (Recovery, days 4e6) there was an increase in collagen loss in the IL-1a group starting on day 4 while in
the Loadþ IL-1a group an increase in collagen loss was delayed until day 5. Data are means S.E.M. for n¼ 10 explants.
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and Loadþ IL-1a groups on day 4. No aggrecan fragments
were detected for the Control group on any day nor for the
Load and Loadþ IL-1a groups on days 0e3 and 5e6.Discussion
Previously we used our in vitro METS to produce an OA-
like cellular response and ECM damage in mature bovine
articular cartilage when loaded with a stress 1 MPa forFig. 7. Aggrecan fragments released into the media before (day 0, D0) a
D4eD6) were measured by Western blot analysis using antibodies w
(G1eG2) domain (BC-3 and AF-28/BC-14 for aggrecanase and MMP g
No aggrecan fragments were found in the Control group (C) on any day
was detected only on day 4 (only D4 is shown). In the IL-1a (IL-1) group ag
the greatest amount of fragments occurring on day 2. Load inhibited IL-1-
both enzyme cleavage sites were detec24 h4,12,23. Our METS cyclically loads the ECM in con-
ﬁned compression, a conﬁguration that simulates one as-
pect of the functional environment within a joint where the
compressive stress applied to the articular surface causes
ﬂuid (water) and solute transport (i.e., IL-1, aggrecan frag-
ments, nutrients) across the surface. In this study we loaded
explants with smaller stresses (0.2e0.5 MPa) for longer
times (3 days) and studied the cellular response to these
loads individually and when applied simultaneously with
an inﬂammatory cytokine (IL-1). We hypothesized that ad-
ministration of both stimuli would result in an acceleratednd during treatment (days 1e3, D1eD3) and recovery (days 4e6,
hich recognize aggrecan cleavage sites within the interglobular
enerated cleavage, respectively; G1 recognizes the G1 domain).
(only D1 is shown). In the Load (L) group the G1 domain fragment
grecan cleavage by both enzymes was detected on days 1e4, with
induced aggrecan cleavage by both enzymes except on day 4 were
ted (Lþ IL-1; only D4 is shown).
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0.5 MPa stress inhibited the IL-1-induced cellular catabo-
lism of the ECM while the 0.2 MPa stress had no effect.
To our knowledge this is the ﬁrst study to evaluate the cou-
pled effects of IL-1 and mechanical load on ECM degrada-
tion in full-thickness, native, mature articular cartilage.
Similar to other studies3,5,29 we found that exposure of
unloaded, free-swelling articular cartilage to IL-1 over a 6-
day interval resulted in aggrecan cleavage and loss to the
media (Figs. 3e5). Western blot analysis of aggrecan frag-
ments revealed that cleavage within the IGD was at two dif-
ferent sites attributed to aggrecanase and MMP activity
(Asn373-Ala374 and Asn341-Phe342 bonds, respectively).
Both cleavage-site fragments appeared at equivalent times
after IL-1 administration (Fig. 7), which differs from previous
ﬁndings in which aggrecan was initially cleaved by aggreca-
nases and at a later time by MMPs3,29,30. While we cannot
explain this difference, it is most likely due to differences in
specie (bovine vs human), age (immature vs mature), joint
(knee vs ankle), tissue type (articular vs nasal), explant ge-
ometry (full-thickness vs partial), stimulus interval, and even
the test conﬁguration (conﬁned vs unconﬁned).
Application of a cyclic mechanical load of 0.2 or 0.5 MPa
for 3 days did not cause ECM degradation compared to
unloaded, free-swelling controls. This result is not unique
as similar ﬁndings have been reported for loads 0.5 MPa
under a variety of different loading regimes (unconﬁned,
intermittent, duration)31e34. Based on these and other stud-
ies35,36 we can hypothesize that a cyclic stress of 0.5 MPa
applied to the ECM (equivalent static stress of 0.35 MPa) is
probably below the level needed to cause a signiﬁcant cat-
abolic response by the chondrocytes. However, this hypoth-
esis needs to be validated especially considering the
inhomogeneous and anisotropic properties of the ECM
where local deformations are signiﬁcantly greater at the ar-
ticular surface then in the deeper zones36,37.
One of the most interesting ﬁndings of our study was that
a 0.2 MPa cyclic stress applied concurrently with IL-1a
(10 ng/ml) had no effect on ECM degradation while
a 0.5 MPa stress signiﬁcantly inhibited the IL-1a-induced
ECM degradation. Similar to our lower stress, Shin et al.38
reported that IL-1-induced (1 ng/ml) PG loss in meniscal
ﬁbrocartilage explants was not inhibited by cyclic compres-
sion (0.1 MPa, 0.5 Hz, 24 h). On the contrary, our higher
stress almost completely inhibited the increased PG loss
caused by the IL-1 stimulation (Fig. 5) while completely
inhibiting aggrecan cleavage within the IGD as no frag-
ments were found in the media until after load removal on
day 4 (Fig. 6). The absence of aggrecan cleavage products
within the ECM was later conﬁrmed by Western blot analy-
ses (data not shown). This unique ﬁnding has not been pre-
viously reported and indicates that mechanical loads
>0.2 MPa applied to native articular cartilage may have
an anti-inﬂammatory role in counteracting the degradative
affects of IL-1. At present the exact mechanism for the inhi-
bition is not known but probably involves preservation of the
mechanobiological signal-transduction pathways between
the ECM and the chondrocyte.
Several other studies have reported similar inhibitory af-
fects of a mechanical stimulus on chondrocyte response
to IL-1 (10 ng/ml) stimulation. However different from our
METS conﬁguration which applied a cyclic load (stress) to
native cartilage in conﬁned compression, these studies ap-
plied a cyclic deformation (strain) to isolated chondrocytes
(monolayer tensile) or to chondrocyte-seeded agarose
gels (unconﬁned compression). While different these cell-
based conﬁgurations can help explain possible inhibitorymechanisms when loading intact cartilage using our
METS. Agarwal et al.16,19e21,39 reported that tensile strain
(3%, 20%) inhibited or reduced IL-1-induced increases in
gene expression (mRNA) for nitric oxide (NO), inducible ni-
tric oxide synthase (iNOS), tumor necrosis factor (TNF)-a,
cyclo-oxygenase (COX)-2, and MMP-3, 7, 8, 9, 13, 16, 17
and 19, had no affect on MMP-2, 11 and 14 and Tissue In-
hibitor of Metalloprotinease-1, 2 and 3 (TIMPs), and re-
versed IL-1 inhibition of aggrecan synthesis. They
concluded that the tensile strain acts at multiple sites within
the NF-kB signaling pathway. Likewise, Chowdbury
et al.17,18,40 found a compressive strain (15%) inhibited
IL-1-induced increases in synthesis of NO and prostaglan-
din-E2 and mRNA for iNOS and COX-2, and that the me-
chanical affect involved the p38 mitogen-activated protein
kinase (MAPK) dependent pathway. Contrary to these in-
hibitory effects, Lima et al.41 reported that a compressive
strain (10% 5%) did not counteract the catabolic effects
of IL-1-induced loss of GAG content and mechanical prop-
erties in long-term (45 days) chondrocyte-gel cultures.
However, this result was confounded by the presence in
the culture media of dexamethasone (0.1 mM) and trans-
forming growth factor-beta (TGF-b) (10 ng/ml), two cyto-
kines that can be mutually antagonistic, regulate the gene
expression for MMPs, and inhibit IL-1-induced ECM degra-
dation42e46. In either case, these results indicate that under
a variety of loading conditions and conﬁgurations, a me-
chanical stimulus of sufﬁcient magnitude and duration can
counteract the IL-1-induced catabolic degradation of the
cartilage ECM.
Once the load and IL-1a stimulations were removed
(recovery >72 h) the ECM degradation was found to
increase dramatically for the next 24 h (96 h, Fig. 5; day
4, Fig. 7) and then gradually decrease over the next 48 h
(120 and 144 h, Fig. 5). What caused the large increase
in PG release after the load and IL-1a were removed is
not known. Several mechanisms are possible: a cellular
catabolic response due to the removal of the load and IL-
1a; residual IL-1a in the ECM after load removal; release
of trapped aggrecan fragments within the compressed
ECM; or continued catabolism from the previous 3 days.
It is unlikely that a catabolic response resulted from the si-
multaneous removal of both stimuli since a similar re-
sponse was not observed in the Load or IL-1 groups. On
the other hand, aggrecan entrapment within the ECM prob-
ably occurred during cyclic loading as we have previously
reported on this mechanism47 Even though aggrecan en-
trapment may have occurred in both loaded groups, it
can only partially explain the increase in aggrecan release
in the Loadþ IL-1 group since this did not occur in the
Load group (Fig. 5). In addition, only intact aggrecan was
released to the media during loading in both groups while
aggrecan fragments were released only in the Loadþ IL-
1 group on day 4 (Fig. 7). Finally aggrecan fragments
were not found within the ECM of any group on day 3,
thus ruling out fragment entrapment (Western blot analy-
sis; data not shown).
The most likely mechanism responsible for the increased
aggrecan release after both stimuli were removed appears
to be from residual IL-1a in the ECM. Since aggrecan re-
lease in the IL-1 group signiﬁcantly decreased after IL-1a
removal, it may be that the concentration of residual IL-1a
in the Loadþ IL-1 group was greater than in the IL-1 group,
causing continued aggrecan degradation. However, a de-
layed or inhibited cellular response cannot be ruled out.
Concomitant with aggrecan proteolysis in the later stages
of degeneration is collagen cleavage by collagenases
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delay in collagen loss (days 4e6) in response to IL-1
stimulation (Fig. 6). On the other hand, the mechanical
load did not affect the collagen loss during or after stimula-
tion nor during stimulation when combined with IL-1. Similar
to the aggrecan loss, we found increased collagen loss after
both stimuli were removed but delayed 1 day (day 5) com-
pared to the aggrecan loss (day 4). Whether the mechanical
load inhibited the catabolism of the collagen during loading
cannot be assessed, however, it does appear that the load-
ing did delay the collagen loss.
In summary, we examined the effect of mechanical load
on the degradation of the ECM by IL-1 and found that
a 0.2 MPa stress had no effect while 0.5 MPa almost com-
pletely inhibited the IL-1-induced degradation during load-
ing. The mechanism responsible for the inhibition appears
to be at the cellular level from an as yet unknown mechano-
chemical signal-transduction pathway. Further studies will
be required to fully understand how different magnitudes,
durations and patterns of mechanical load affect cartilage
health and degradation in the presence of inﬂammatory cy-
tokines such as IL-1 and TNF-a.Conﬂict of interest
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